ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Ravi Madan discussing preliminary data from 6 month follow-up assessing prospective monitoring of PSMA–positive ...

The score ranges from 6 to 10 because grades 1 and 2 are rarely used for cancer diagnosis. (a score of 1-2 means that you do not have cancer) A lower ...

Research on cancer metastasis uncovers genetic complexities, showing that copy-number alterations play a key role in tumor ...

Johnson & Johnson (NYSE:JNJ) said on Tuesday that niraparib, a cancer treatment from a group of drugs called PARP inhibitors, ...

"PARP inhibitors have been a mainstay in the treatment of metastatic castration-resistant prostate cancer for patients with ...

Zejula with Zytiga and prednisone delayed cancer growth and symptoms in patients with castration-sensitive prostate cancer ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

Novartis has reported topline outcomes from the Phase III PSMAddition trial’s pre-specified interim analysis of Pluvicto.

With early detection of prostate cancer recognised as a critical part in reducing the disease’s mortality rate, PanGIA ...

Prostate cancer remains the most common cancer in men and the second deadliest. The median age of diagnosis is 67. Yet, ...

Many people with advanced prostate cancer are living much longer due to new treatments, leading prostate cancer doctors say.

Daniel J. Stone Former President Joe Biden’s metastatic cancer diagnosis brings together two controversial issues: PSA testing for prostate cancer and presidential politics.  To understand what is at ...